ArticleJournal of interventional cardiology2019
Long-Term Outcomes of Extent of Revascularization in Complex High Risk and Indicated Patients Undergoing Impella-Protected Percutaneous Coronary Intervention: Report from the Roma-Verona Registry.
Article in Journal of interventional cardiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 1 synthesis or guideline pooled it, 53 citations in OpenAlex.
- Comparative safety of percutaneous ventricular assist device and intra-aortic balloon pump in acute myocardial infarction-induced cardiogenic shock.Open heart · 2021Pooled it
- Contemporary evidence in protected percutaneous coronary intervention: a case-based review.European heart journal supplements : journal of the European Society of Cardiology · 2026Article
- Impella™-protected PCI in a post-CABG patient with advanced biventricular dysfunction and mitral regurgitation.European heart journal supplements : journal of the European Society of Cardiology · 2026Article
- Optimizing revascularization in the high-risk heart: Impella™-facilitated percutaneous coronary intervention in multivessel coronary artery disease with reduced left ventricular ejection fraction and mitral regurgitation.European heart journal supplements : journal of the European Society of Cardiology · 2026Article
- Patient selection for complex, high-risk indicated percutaneous coronary intervention procedures: an overview.European heart journal supplements : journal of the European Society of Cardiology · 2026Article
- Impella vs. IABP in Non-emergent High-Risk PCI: Outcomes and LVEF Recovery from a Large US EHR Study.Cardiology and therapy · 2026Article
- Preprocedural vascular sheath insertion reduces hospital mortality in high risk PCI patients.Scientific reports · 2026Article
- Article
- Evaluation of LVEDP Change During High-Risk PCI With and Without Impella Support (ELVIS)-A Pilot Trial.Journal of clinical medicine · 2025Article
- High-risk percutaneous coronary intervention in patients with reduced left ventricular ejection fraction deemed not suitable for surgical revascularisation. A clinical consensus statement from the European Association of Percutaneous Cardiovascular Interventions (EAPCI) in collaboration with the ESC Working Group on Cardiovascular Surgery.EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology · 2025Article
- Pulsatile Left Ventricular Assistance in High-Risk Percutaneous Coronary Interventions: Short-Term Outcomes.Journal of clinical medicine · 2024Article
- Mechanical Circulatory Support with Impella: Principles, Evidence, and Daily Practice.Journal of clinical medicine · 2024Review
- The use of mechanical circulatory support in elective high-risk percutaneous coronary interventions: a literature-based review.European heart journal open · 2024Review
- Change in left ventricular function and outcomes following high-risk percutaneous coronary intervention with Impella-guided hemodynamic support.Frontiers in cardiovascular medicine · 2024Article
- Predictors of left ventricular ejection fraction in high-risk percutaneous coronary interventions.Frontiers in cardiovascular medicine · 2024Article
- Comparison of Outcomes of Elective Percutaneous Coronary Intervention between Complex and High-Risk Intervention in Indicated Patients (CHIP) versus Non-CHIP.Journal of atherosclerosis and thrombosis · 2023Article
- Complex and high-risk intervention in indicated patients (CHIP) in contemporary clinical practice.Cardiovascular intervention and therapeutics · 2023Review
- The Impact of Complete Revascularization in Symptomatic Severe Left Ventricular Dysfunction between Coronary Artery Bypass Graft and Percutaneous Coronary Intervention.Cardiology research and practice · 2023Article
- Short-term mechanical support with the Impella 5.x for mitral valve surgery in advanced heart failure-protected cardiac surgery.Frontiers in cardiovascular medicine · 2023Article
- Defining the optimal revascularization strategy during protected high-risk procedures with Impella.European heart journal supplements : journal of the European Society of Cardiology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the effect of extent of revascularization in complex high-risk indicated patients (CHIP) undergoing Impella-protected percutaneous coronary intervention (PCI).
backgroundComplete revascularization has been shown to be associated with improved outcomes. However, the impact of more complete revascularization during Impella-protected PCI in CHIP has not been reported.
methodsA total of 86 CHIP undergoing elective PCI with Impella 2.5 or Impella CP between April 2007 and December 2016 from 2 high volume Italian centers were included. Baseline, procedural, and clinical outcomes data were collected retrospectively. Completeness of coronary revascularization was assessed using the British Cardiovascular Intervention Society myocardial jeopardy score (BCIS-JS) derived revascularization index (RI). The primary end-point was all-cause mortality. A multivariate regression model was used to identify independent predictors of mortality.
resultsAll patients had multivessel disease and were considered unsuitable for surgery. At baseline, 44% had left main disease, 78% had LVEF ≤ 35%, and mean BCIS-JS score was 10±2. The mean BCIS-JS derived RI was 0.7±0.2 and procedural complications were uncommon. At 14-month follow-up, all-cause mortality was 10.5%. At follow-up, 67.4% of CHIP had LVEF ≥ 35% compared to 22.1% before Impella protected-PCI. Higher BCIS-JS RI was significantly associated with LVEF improvement (p=0.002). BCIS-JS RI of ≤ 0.8 (HR 0.11, 95% CI 0.01- 0.92, and p = 0.042) was an independent predictor of mortality.
conclusionsThese results support the practice of percutaneous Impella use for protected PCI in CHIP. A more complete revascularization was associated with significant LVEF improvement and survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.